BBB National Programs Newsroom

NAD Finds Health-Related Claims for Pendulum Glucose Control Medical Probiotic Supported but Recommends Some Modifications

For Immediate Release 
Contact: Abby Hills, Director of Communications, BBB National Programs 
703.247.9330 / press@bbbnp.org

New York, NY – March 3, 2021 – The National Advertising Division (NAD) of BBB National Programs determined that certain claims for Pendulum Glucose Control, manufactured by Pendulum Therapeutics, Inc. to help Type 2 diabetes dietary management, were supported by competent and reliable scientific evidence:   
  • “The only medical probiotic clinically shown to lower A1C & blood glucose spikes for the dietary management of T2D* (*Consult your physician as part of your total diabetes management plan. Results may vary from person to person)”; and  
  • “The only probiotic clinically shown to lower glucose spikes by 33% and reduce A1C levels by 0.6 in people with type 2 diabetes.” 

 

However, NAD recommended the following modifications so that the claims more accurately reflect the limitations in the evidence by: 

  • Limiting the claims to individuals who are taking metformin;  
  • Modifying the claims to clarify that the product can be used as part of the dietary management of type 2 diabetes; and 
  • Removing references to percent reductions in blood glucose spikes in the absence of evidence in the record demonstrating that the reductions were clinically relevant. 

 

The claims at issue were challenged as part of NAD’s routine monitoring program. During the pendency of the case, the advertiser voluntarily modified many of the challenged claims permanently, therefore, NAD did not review these claims on the merits. 

In support of its claims, the advertiser chiefly relied on the Perraudeau Study assessing Pendulum Glucose Control’s effectiveness in helping Type 2 diabetes dietary management. NAD determined that this study had some appropriate methodological components (double-blind, randomized, placebo-controlled, sufficiently large sample size to elicit statistically significant and clinically meaningful results, testing the marketed product, clearly defined endpoints). However, NAD questioned certain aspects of the study related to test population and clinical relevance of the endpoints.  

Based on its assessment, NAD determined that the Perraudeau study was a good fit for the challenged claims but recommended the previously noted modifications. 

In its advertiser statement, Pendulum Therapeutics, Inc. stated that it “is pleased with NAD’s decision and will comply with its recommendations.” 

All BBB National Programs case decisions can be found in the case decision library.  

### 

About BBB National Programs: BBB National Programs is where businesses turn to enhance consumer trust and consumers are heard. The non-profit organization creates a fairer playing field for businesses and a better experience for consumers through the development and delivery of effective third-party accountability and dispute resolution programs. Embracing its role as an independent organization since the restructuring of the Council of Better Business Bureaus in June 2019, BBB National Programs today oversees more than a dozen leading national industry self-regulation programs, and continues to evolve its work and grow its impact by providing business guidance and fostering best practices in arenas such as advertising, child-directed marketing, and privacy. To learn more, visit bbbprograms.org. 

About the National Advertising Division: The National Advertising Division (NAD), a division of BBB National Programs, provides independent self-regulation and dispute resolution services, guiding the truthfulness of advertising across the U.S. NAD reviews national advertising in all media and its decisions set consistent standards for advertising truth and accuracy, delivering meaningful protection to consumers and leveling the playing field for business.     

NAD Finds Health-Related Claims for Pendulum Glucose Control Medical Probiotic Supported but Recommends Some Modifications

For Immediate Release 
Contact: Abby Hills, Director of Communications, BBB National Programs 
703.247.9330 / press@bbbnp.org

New York, NY – March 3, 2021 – The National Advertising Division (NAD) of BBB National Programs determined that certain claims for Pendulum Glucose Control, manufactured by Pendulum Therapeutics, Inc. to help Type 2 diabetes dietary management, were supported by competent and reliable scientific evidence:   
  • “The only medical probiotic clinically shown to lower A1C & blood glucose spikes for the dietary management of T2D* (*Consult your physician as part of your total diabetes management plan. Results may vary from person to person)”; and  
  • “The only probiotic clinically shown to lower glucose spikes by 33% and reduce A1C levels by 0.6 in people with type 2 diabetes.” 

 

However, NAD recommended the following modifications so that the claims more accurately reflect the limitations in the evidence by: 

  • Limiting the claims to individuals who are taking metformin;  
  • Modifying the claims to clarify that the product can be used as part of the dietary management of type 2 diabetes; and 
  • Removing references to percent reductions in blood glucose spikes in the absence of evidence in the record demonstrating that the reductions were clinically relevant. 

 

The claims at issue were challenged as part of NAD’s routine monitoring program. During the pendency of the case, the advertiser voluntarily modified many of the challenged claims permanently, therefore, NAD did not review these claims on the merits. 

In support of its claims, the advertiser chiefly relied on the Perraudeau Study assessing Pendulum Glucose Control’s effectiveness in helping Type 2 diabetes dietary management. NAD determined that this study had some appropriate methodological components (double-blind, randomized, placebo-controlled, sufficiently large sample size to elicit statistically significant and clinically meaningful results, testing the marketed product, clearly defined endpoints). However, NAD questioned certain aspects of the study related to test population and clinical relevance of the endpoints.  

Based on its assessment, NAD determined that the Perraudeau study was a good fit for the challenged claims but recommended the previously noted modifications. 

In its advertiser statement, Pendulum Therapeutics, Inc. stated that it “is pleased with NAD’s decision and will comply with its recommendations.” 

All BBB National Programs case decisions can be found in the case decision library.  

### 

About BBB National Programs: BBB National Programs is where businesses turn to enhance consumer trust and consumers are heard. The non-profit organization creates a fairer playing field for businesses and a better experience for consumers through the development and delivery of effective third-party accountability and dispute resolution programs. Embracing its role as an independent organization since the restructuring of the Council of Better Business Bureaus in June 2019, BBB National Programs today oversees more than a dozen leading national industry self-regulation programs, and continues to evolve its work and grow its impact by providing business guidance and fostering best practices in arenas such as advertising, child-directed marketing, and privacy. To learn more, visit bbbprograms.org. 

About the National Advertising Division: The National Advertising Division (NAD), a division of BBB National Programs, provides independent self-regulation and dispute resolution services, guiding the truthfulness of advertising across the U.S. NAD reviews national advertising in all media and its decisions set consistent standards for advertising truth and accuracy, delivering meaningful protection to consumers and leveling the playing field for business.     

Blog

Enhancing Brand Safety: Understanding Self-Regulation vs. Independent Industry Self-Regulation

With copious amounts of content proliferating across a growing number of platforms and websites, it is an ongoing challenge for advertisers and platforms to ensure that digital ads are not placed next to harmful content. In this conversation, there is a key distinction few are making — the difference between ‘self-regulation’ and ‘independent, industry-wide self-regulation.’
Read more
Blog

CFBAI and CCAI Published the 2020 Annual Report on Participant Compliance and Program Progress

BBB National Programs has released the CFBAI and CCAI 2020 Annual Report, which includes findings on CFBAI and CCAI participant compliance with their commitment to advertise only foods that meet CFBAI’s strict Uniform Nutrition Criteria or to not engage in advertising primarily directed to children under age 12. The Report indicates excellent compliance by the 19 CFBAI participants and the eight CCAI participants in 2020.
Read more
Blog

What Do You Need to Know about the Florida Lemon Law?

If you have ever purchased or leased a car or SUV that you consider a lemon, you may have questions about the myriad of federal and state laws that govern your vehicle and the remedies available to you. Each state also has their own statute governing vehicles sold and leased in that state for personal use. Today, we look at the lemon law in Florida, one of the fastest-growing states in the U.S.
Read more
Blog

AI Can Be A Force For Good In Recruiting And Hiring New Employees

A challenge for rapid innovation in any industry is the ability for legal and regulatory requirements to keep pace. In the recruiting and hiring process, where AI provides aid to human decision-making and a welcome relief to managing a deluge of data, company leaders are asking themselves: How can we combine important technological innovation with a proactive approach to employment law requirements?
Read more

NAD Finds Health-Related Claims for Pendulum Glucose Control Medical Probiotic Supported but Recommends Some Modifications

For Immediate Release 
Contact: Abby Hills, Director of Communications, BBB National Programs 
703.247.9330 / press@bbbnp.org

New York, NY – March 3, 2021 – The National Advertising Division (NAD) of BBB National Programs determined that certain claims for Pendulum Glucose Control, manufactured by Pendulum Therapeutics, Inc. to help Type 2 diabetes dietary management, were supported by competent and reliable scientific evidence:   
  • “The only medical probiotic clinically shown to lower A1C & blood glucose spikes for the dietary management of T2D* (*Consult your physician as part of your total diabetes management plan. Results may vary from person to person)”; and  
  • “The only probiotic clinically shown to lower glucose spikes by 33% and reduce A1C levels by 0.6 in people with type 2 diabetes.” 

 

However, NAD recommended the following modifications so that the claims more accurately reflect the limitations in the evidence by: 

  • Limiting the claims to individuals who are taking metformin;  
  • Modifying the claims to clarify that the product can be used as part of the dietary management of type 2 diabetes; and 
  • Removing references to percent reductions in blood glucose spikes in the absence of evidence in the record demonstrating that the reductions were clinically relevant. 

 

The claims at issue were challenged as part of NAD’s routine monitoring program. During the pendency of the case, the advertiser voluntarily modified many of the challenged claims permanently, therefore, NAD did not review these claims on the merits. 

In support of its claims, the advertiser chiefly relied on the Perraudeau Study assessing Pendulum Glucose Control’s effectiveness in helping Type 2 diabetes dietary management. NAD determined that this study had some appropriate methodological components (double-blind, randomized, placebo-controlled, sufficiently large sample size to elicit statistically significant and clinically meaningful results, testing the marketed product, clearly defined endpoints). However, NAD questioned certain aspects of the study related to test population and clinical relevance of the endpoints.  

Based on its assessment, NAD determined that the Perraudeau study was a good fit for the challenged claims but recommended the previously noted modifications. 

In its advertiser statement, Pendulum Therapeutics, Inc. stated that it “is pleased with NAD’s decision and will comply with its recommendations.” 

All BBB National Programs case decisions can be found in the case decision library.  

### 

About BBB National Programs: BBB National Programs is where businesses turn to enhance consumer trust and consumers are heard. The non-profit organization creates a fairer playing field for businesses and a better experience for consumers through the development and delivery of effective third-party accountability and dispute resolution programs. Embracing its role as an independent organization since the restructuring of the Council of Better Business Bureaus in June 2019, BBB National Programs today oversees more than a dozen leading national industry self-regulation programs, and continues to evolve its work and grow its impact by providing business guidance and fostering best practices in arenas such as advertising, child-directed marketing, and privacy. To learn more, visit bbbprograms.org. 

About the National Advertising Division: The National Advertising Division (NAD), a division of BBB National Programs, provides independent self-regulation and dispute resolution services, guiding the truthfulness of advertising across the U.S. NAD reviews national advertising in all media and its decisions set consistent standards for advertising truth and accuracy, delivering meaningful protection to consumers and leveling the playing field for business.     

 

 

Media Inquiry